Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors-Reference-Cited by-同舟云学术

Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors

Published:2024-04-18 Issue:12 Volume:130 Page:1943-1950
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Chang Ching-Yuan,Jones Bobby L.,Hincapie-Castillo Juan M.,Park Haesuk,Heldermon Coy D.,Diaby Vakaramoko,Wilson Debbie L.^ORCID,Lo-Ciganic Wei-Hsuan^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02680-0.pdf

Reference64 articles.

1. Surveillance, Epidemiology, and End Results Program National Center for Health Statistics. Cancer Stat Facts: Female breast cancer. 2019. https://seer.cancer.gov/statfacts/html/breast.html.

2. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69.

3. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20:691–722.

4. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.

5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.